Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Approvals Action
MSD's new anti-infective registered
MSD's new treatment for clostridium difficile infection has been registered on the ARTG after consideration by the PBAC earlier this month.
Pipeline Monitor
Bumper week for AZ
AstraZeneca has registered regulatory wins for cancer drug Faslodex and new asthma biologic Fasenra in a busy week for the Anglo-Swedish company.
Perspective
Why health bureaucrats need to do yoga
As health bureaucrats mull over a unique funding deal slapped down on the table by a drug sponsor looking to find a new path to reimbursement, they may find learning a few yoga moves useful.